19:50 Uhr
ROUNDUP: Scholz: Handelsstreit mit den USA könnte EU-​Integration vorantreiben

Spherix Announces the Addition of Dr. Scott T. Tagawa to Company's Technology Advisory Board

Dienstag, 15.08.2017 14:05 von PR Newswire

PR Newswire

NEW YORK, Aug. 15, 2017 /PRNewswire/ -- Spherix Incorporated ("Spherix" or the "Company") (NASDAQ: SPEX), an intellectual property development company committed to the fostering of technology, today announced the addition of Dr. Scott T. Tagawa to the Company's Technology Advisory Board.  The Technology Advisory Board was formed to assist the Company in evaluating potential opportunities in the biopharmaceutical arena.

Spherix Logo. (PRNewsFoto/Spherix Incorporated)

Dr. Scott T. Tagawa, MD, MS is the Richard A. Stratton Associate Professor in Hematology and Oncology and an Associate Professor of Clinical Medicine and of Clinical Urology at Weill Cornell Medicine. After earning his BS from Georgetown University, Dr. Tagawa received his MD at the University of Southern California School of Medicine. After completing his Internship and Residency training there, he became Chief Resident and subsequently underwent fellowship training in Hematology and Medical Oncology, being appointed Chief Fellow for his final two years. In August 2005, he was appointed Assistant Professor of Medicine at Mount Sinai School of Medicine, serving as Associate Program Director for the Fellowship Training Program. As Director of Genitourinary Oncology for the Division of Hematology and Oncology and Director of Medical Oncology for the Deane Prostate Health and Research Center, Dr. Tagawa took the lead in developing genitourinary clinical trials. He was recruited to Weill Cornell Medicine in 2007. His research covers clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theragnostic in prostate cancer. He was promoted to Associate Professor of Clinical Medicine and of Clinical Urology in 2013. Dr. Tagawa is the Weill Cornell Medicine principal investigator for the Alliance for Clinical Trials in Oncology (formerly CALGB), serving on the Board of Directors and as a funded member of the Genitourinary Committee. Additionally, he serves on the editorial boards of many journals, is a member of numerous national and international medical and scientific societies, and has been named on multiple "top doctor" award lists. 

Anthony Hayes, the Chief Executive Officer of Spherix stated, "Dr. Tagawa is clearly a leader in his field, with an exceptionally distinguished career. We are honored to have him on our advisory board and grateful for his assistance in vetting opportunities for the Company."

About Spherix Incorporated
Spherix Incorporated was launched in 1967 as a scientific research company. Spherix is committed to advancing innovation by participation in the development of new technology. Spherix draws on portfolios of pioneering technology to support product innovation.

Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. We are a small company with limited financial resources and our scientific background and abilities to implement a commercialization strategy is subject to ever-changing market conditions and rapidly-advancing technologies over which we have no control. While we believe that these forward-looking statements are reasonable, market conditions and competition in the marketplace is ever-changing and we have no control over these influences. As a result, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC") including, but not limited to, the Risk Factors relating to the Company's patent business and other aspects of the Company's business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.


Investor Relations Contact:
Hayden IR, LLC
Brett Mass
Phone: (646) 536-7331

Spherix Contact:
Phone: (703) 992-9325

View original content with multimedia:

SOURCE Spherix Incorporated